
Small Scale, Big Impact: Efficient AAV Feasibility Studies with Pharmaron
Developing adeno-associated virus (AAV) platforms is pivotal in advancing biologics and cell & gene therapies. Pharmaron’s small-scale feasibility studies and advanced QC release testing provide a cost-effective and efficient pathway to assess viral vector performance early in your product lifecycle. By leveraging cutting-edge technologies, our platform minimizes risk while accelerating your program’s progression.
Efficient and Scalable Solutions
Pharmaron’s platform is built for flexibility, using state-of-the-art tools like AMBR 250mL platform processes, chromatography-based purification, and tailored platform analytics. With access to HEK293 cell lines, RepCap plasmids, and both client- and Pharmaron-generated transgenes, we ensure that every project’s unique needs are met. Whether you’re developing for research or clinical use, our capabilities deliver precise insights to inform your next steps.

Key Deliverables to Drive Decisions
Our studies provide critical outputs, including:
- Analytical data for process optimization
- Titre and Empty-to-Full capsid ratio evaluations for drug substances
- Transgene performance analysis with actionable optimization recommendations
These results empower you to refine your AAV process early, saving time and resources while maintaining quality standards.
Small Volume Testing: Big Advantages
Pharmaron’s innovative small-volume analytics enable the comprehensive characterization of AAV studies with reduced sample requirements. We ensure exceptional sensitivity and accuracy using assays like Capsid ELISA, droplet digital PCR, and mass photometry. Small volumes conserve material and support scalability, allowing more batches to be analyzed—a critical advantage for clinical and comparability studies.
QC Excellence for Advanced Testing
Our commitment to quality extends into QC release testing, ensuring robust analysis of drug substances (DS) and drug products (DP). Key advancements include:
- Reduced sample volumes for impurity and endotoxin testing
- Highly sensitive fluorescence detectors for key quality attributes like titre, aggregation, and impurities
By integrating small-volume techniques, Pharmaron helps you achieve high-quality results with minimal product usage, maximizing efficiency and batch availability for clinical studies.
Accelerate Your Pathway to Success
Pharmaron’s feasibility studies, with rapid 6–8-week timelines, are tailored to deliver actionable insights while optimizing your AAV process. Whether you’re still selecting a candidate or evaluating multiple constructs, our platform provides the support and expertise needed to advance your program confidently.